Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 3/20 | 0.38 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17866275 | 0.88 | CNR1 (0.45) | KDM4ENPC1RAB9ACNR1PTGS2 | |
| SCHEMBL2114119 | 0.83 | CNR1 (0.48) | NPC1CNR1GRM1PTGS2KCNH2 | |
| SCHEMBL2112797 | 0.83 | CNR1 (0.49) | KDM4ENPC1RAB9ACNR1PTGS2 | |
| SCHEMBL2113240 | 0.83 | CNR1 (0.47) | NPC1RAB9ACNR1GAARAF1 | |
| SCHEMBL2112615 | 0.82 | CNR1 (0.51) | KDM4ENPC1RAB9ACNR1PTGS2 | |
| SCHEMBL2115870 | 0.82 | CNR1 (0.56) | KDM4ENPC1RAB9ACNR1PTGS2 | |
| SCHEMBL2114245 | 0.82 | CNR1 (0.50) | RAB9ACNR1PTGS2KCNH2SCN5A | |
| SCHEMBL2113753 | 0.81 | CNR1 (0.48) | KDM4ECNR1PTGS2KCNH2SCN5A | |
| SCHEMBL2112859 | 0.81 | NPC1 (0.54) | NPC1RAB9ACNR1NAMPTPTGS2 | |
| SCHEMBL2113414 | 0.81 | CNR1 (0.54) | KDM4ECNR1PTGS2KCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | claimed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | claimed |
| EP-2627637-B1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | APOB, CETP, NPC1L1 | KDM4E 1664/4885NPC1 7/4885RAB9A 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.